Alopecia overview: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Alopecia}}
{{Alopecia}}
{{CMG}}
{{CMG}} [[Ogechukwu Hannah Nnabude, MD]]
==Overview==
==Overview==
Alopecia is defined as loss of hair regardless of the cause. It can occur anywhere on the body. The hair cycle consists of three phases: '''anagen phase''', which is the growth phase, '''catagen phase''', which is the resting phase, and '''telogen phase''', which is the shedding phase. This is the phase where hair falls out. <ref name="pmid30520225">{{cite journal| author=Monib KME, Hussein MS, Kandeel WS| title=The relation between androgenetic thin hair diagnosed by trichoscope and benign prostatic hyperplasia. | journal=J Cosmet Dermatol | year= 2018 | volume=  | issue=  | pages=  | pmid=30520225 | doi=10.1111/jocd.12835 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30520225  }} </ref>  
Alopecia is defined as loss of hair regardless of the cause. It can occur anywhere on the body. The hair cycle consists of three phases: '''anagen phase''', which is the growth phase, '''catagen phase''', which is the resting phase, and '''telogen phase''', which is the shedding phase. This is the phase where hair falls out. <ref name="pmid30520225">{{cite journal| author=Monib KME, Hussein MS, Kandeel WS| title=The relation between androgenetic thin hair diagnosed by trichoscope and benign prostatic hyperplasia. | journal=J Cosmet Dermatol | year= 2018 | volume=  | issue=  | pages=  | pmid=30520225 | doi=10.1111/jocd.12835 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30520225  }} </ref>  
Ninety percent of hair are in the anagen phase and the remaining ten percent are in the catagen and telogen phases. <ref name="pmid30520145">{{cite journal| author=Gordon SC, Abudu M, Zancanaro P, Ko JM, Rosmarin D| title=Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata. | journal=J Eur Acad Dermatol Venereol | year= 2019 | volume= 33 | issue= 4 | pages= e156-e157 | pmid=30520145 | doi=10.1111/jdv.15383 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30520145  }} </ref> In the telogen phase, hair is going to recycle, and it starts growing again in the  anagen phase. <ref name="pmid30519542">Spaich S, Kinder J, Hetjens S, Fuxius S, Gerhardt A, Sütterlin M (2018) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=30519542 Patient Preferences Regarding Chemotherapy in Metastatic Breast Cancer-A Conjoint Analysis for Common Taxanes.] ''Front Oncol'' 8 ():535. [http://dx.doi.org/10.3389/fonc.2018.00535 DOI:10.3389/fonc.2018.00535] PMID: [https://pubmed.gov/30519542 30519542]</ref>
Ninety percent of hair are in the anagen phase and the remaining ten percent are in the catagen and telogen phases. <ref name="pmid30520145">{{cite journal| author=Gordon SC, Abudu M, Zancanaro P, Ko JM, Rosmarin D| title=Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata. | journal=J Eur Acad Dermatol Venereol | year= 2019 | volume= 33 | issue= 4 | pages= e156-e157 | pmid=30520145 | doi=10.1111/jdv.15383 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30520145  }} </ref> In the telogen phase, hair is going to recycle, and it starts growing again in the  anagen phase. <ref name="pmid30519542">Spaich S, Kinder J, Hetjens S, Fuxius S, Gerhardt A, Sütterlin M (2018) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=30519542 Patient Preferences Regarding Chemotherapy in Metastatic Breast Cancer-A Conjoint Analysis for Common Taxanes.] ''Front Oncol'' 8 ():535. [http://dx.doi.org/10.3389/fonc.2018.00535 DOI:10.3389/fonc.2018.00535] PMID: [https://pubmed.gov/30519542 30519542]</ref>


Alopecia can be subdivided into two main categories: scarring and non-scarring.
==Historical Perspectives==
The use of the word alopecia stretches back to the era of the Greek physician Hippocrates. Minoxidil and finasteride are the only FA approved medications for treating alopecia. Hair transplant surgery originated in the 1900s and some of the major advancements in hair transplantation took place in Japan in the 1930s.


The most common type is '''non-scarring or androgenetic alopecia'''. The majority of men start to lose hair in the third decade of life, while women begin to lose their hair in the fifth or sixth decade of life. As an individual ages, they will lose hair. Men more often lose hair in the front and the temporal regions of the scalp, while women tend to lose hair from the central area of the scalp. Also, female hair loss rarely results in complete baldness while male hair loss can end up with complete baldness. Males tend to retain hair at the posterior area of the scalp because the hair in this region is more resistant to the effects of androgenic hormones. <ref name="pmid30506608">{{cite journal| author=Li J, Kong XB, Chen XY, Zhong WZ, Chen JY, Liu Y | display-authors=etal| title=Protective role of α2-macroglobulin against jaw osteoradionecrosis in a preclinical rat model. | journal=J Oral Pathol Med | year= 2019 | volume= 48 | issue= 2 | pages= 166-173 | pmid=30506608 | doi=10.1111/jop.12809 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30506608  }} </ref>
==Classification==
==Classification==


Alopecia is classified as either scarring or non-scarring.
Alopecia is classified as either scarring or non-scarring. Over all, non-scarring alopecias tend to have better outcomes than scarring alopecias, which tend to be irreversible.
The most common type is ''' androgenetic alopecia'''. The majority of men start to lose hair in the third decade of life, while women begin to lose their hair in the fifth or sixth decade of life. As an individual ages, they will lose hair. Men more often lose hair in the front and the temporal regions of the scalp, while women tend to lose hair from the central area of the scalp. Also, female hair loss rarely results in complete baldness while male hair loss can end up with complete baldness. Males tend to retain hair at the posterior area of the scalp because the hair in this region is more resistant to the effects of androgenic hormones. <ref name="pmid30506608">{{cite journal| author=Li J, Kong XB, Chen XY, Zhong WZ, Chen JY, Liu Y | display-authors=etal| title=Protective role of α2-macroglobulin against jaw osteoradionecrosis in a preclinical rat model. | journal=J Oral Pathol Med | year= 2019 | volume= 48 | issue= 2 | pages= 166-173 | pmid=30506608 | doi=10.1111/jop.12809 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30506608  }} </ref>
 
 
==Pathophysiology==
There are several pathophysiologic mechanisms responsible for alopecia, each related to the specific cause. For example, alopecia areata, is related with CD8+ T-cell autoimmunity, while androgenetic alopecia is related to the effects of androgen hormones hair follicles.


==Causes==
==Causes==


Scarring alopecia is caused by numerous dermatologic factors, including glabrous skin (non-hairy), and is very difficult to diagnose and manage.  Non-scarring alopecia is characterized by the absence of visible [[inflammation]] of the [[skin]] involved.
Scarring alopecia is caused by numerous dermatologic factors, including glabrous skin (non-hairy), and is very difficult to diagnose and manage.  Non-scarring alopecia is characterized by the absence of visible [[inflammation]] of the [[skin]] involved. Medications, endocrine diseases, infectious diseases, and autoimmune diseases can also cause hair loss.
 
==Treatment==
==Treatment==
===Medical Therapy===
===Medical Therapy===
In the USA, there are only 2 drug-based treatments that have been approved by the [[FDA]] (Food and Drug Administration) and one product that has been cleared by the [[FDA]] for the treatment of [[androgenetic alopecia]], otherwise known as male or female pattern hair loss. The two FDA approved treatments are [[finasteride]] (marketed for hair loss as [[Propecia]]) and [[minoxidil]].
In the USA, there are only 2 drug-based treatments that have been approved by the [[FDA]] (Food and Drug Administration) and one product that has been cleared by the [[FDA]] for the treatment of [[androgenetic alopecia]], otherwise known as male or female pattern hair loss. The two FDA approved treatments are [[finasteride]] (marketed for hair loss as [[Propecia]]) and [[minoxidil]].

Revision as of 02:47, 3 January 2021

Alopecia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Alopecia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Laser Therapy

Concealing Hair Loss

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Alopecia overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Alopecia overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Alopecia overview

CDC on Alopecia overview

Alopecia overview in the news

Blogs on Alopecia overview

Directions to Hospitals Treating Alopecia

Risk calculators and risk factors for Alopecia overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Ogechukwu Hannah Nnabude, MD

Overview

Alopecia is defined as loss of hair regardless of the cause. It can occur anywhere on the body. The hair cycle consists of three phases: anagen phase, which is the growth phase, catagen phase, which is the resting phase, and telogen phase, which is the shedding phase. This is the phase where hair falls out. [1] Ninety percent of hair are in the anagen phase and the remaining ten percent are in the catagen and telogen phases. [2] In the telogen phase, hair is going to recycle, and it starts growing again in the anagen phase. [3]

Historical Perspectives

The use of the word alopecia stretches back to the era of the Greek physician Hippocrates. Minoxidil and finasteride are the only FA approved medications for treating alopecia. Hair transplant surgery originated in the 1900s and some of the major advancements in hair transplantation took place in Japan in the 1930s.

Classification

Alopecia is classified as either scarring or non-scarring. Over all, non-scarring alopecias tend to have better outcomes than scarring alopecias, which tend to be irreversible. The most common type is androgenetic alopecia. The majority of men start to lose hair in the third decade of life, while women begin to lose their hair in the fifth or sixth decade of life. As an individual ages, they will lose hair. Men more often lose hair in the front and the temporal regions of the scalp, while women tend to lose hair from the central area of the scalp. Also, female hair loss rarely results in complete baldness while male hair loss can end up with complete baldness. Males tend to retain hair at the posterior area of the scalp because the hair in this region is more resistant to the effects of androgenic hormones. [4]


Pathophysiology

There are several pathophysiologic mechanisms responsible for alopecia, each related to the specific cause. For example, alopecia areata, is related with CD8+ T-cell autoimmunity, while androgenetic alopecia is related to the effects of androgen hormones hair follicles.

Causes

Scarring alopecia is caused by numerous dermatologic factors, including glabrous skin (non-hairy), and is very difficult to diagnose and manage. Non-scarring alopecia is characterized by the absence of visible inflammation of the skin involved. Medications, endocrine diseases, infectious diseases, and autoimmune diseases can also cause hair loss.

Treatment

Medical Therapy

In the USA, there are only 2 drug-based treatments that have been approved by the FDA (Food and Drug Administration) and one product that has been cleared by the FDA for the treatment of androgenetic alopecia, otherwise known as male or female pattern hair loss. The two FDA approved treatments are finasteride (marketed for hair loss as Propecia) and minoxidil.

Surgery

Surgery is another method of reversing hair loss and baldness, although it may be considered an extreme measure. The surgical methods used include hair transplantation, whereby hair-producing follicles are taken from the back and sides of the head and injected into bald or thinning areas.

References

  1. Monib KME, Hussein MS, Kandeel WS (2018). "The relation between androgenetic thin hair diagnosed by trichoscope and benign prostatic hyperplasia". J Cosmet Dermatol. doi:10.1111/jocd.12835. PMID 30520225.
  2. Gordon SC, Abudu M, Zancanaro P, Ko JM, Rosmarin D (2019). "Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata". J Eur Acad Dermatol Venereol. 33 (4): e156–e157. doi:10.1111/jdv.15383. PMID 30520145.
  3. Spaich S, Kinder J, Hetjens S, Fuxius S, Gerhardt A, Sütterlin M (2018) Patient Preferences Regarding Chemotherapy in Metastatic Breast Cancer-A Conjoint Analysis for Common Taxanes. Front Oncol 8 ():535. DOI:10.3389/fonc.2018.00535 PMID: 30519542
  4. Li J, Kong XB, Chen XY, Zhong WZ, Chen JY, Liu Y; et al. (2019). "Protective role of α2-macroglobulin against jaw osteoradionecrosis in a preclinical rat model". J Oral Pathol Med. 48 (2): 166–173. doi:10.1111/jop.12809. PMID 30506608.

Template:WikiDoc Sources